RAAS antagonist therapy for prevention of atrial fibrillation in hypertension / 中华全科医师杂志
Chinese Journal of General Practitioners
; (6): 81-84, 2019.
Article
em Zh
| WPRIM
| ID: wpr-734849
Biblioteca responsável:
WPRO
ABSTRACT
Hypertension is the most common and controlable risk factor of atrial fibrillation (AF).Resin-angiotensin-aldosterone system (RAAS) antagonist therapy may reduce atrial remodeling and hold promise as “upstream” therapy for AF,especially for the patients with left ventricular hypertrophy and left ventricular dysfunction.The RAAS antagonist therapy for prevention of AF in hypertensive patients needs to be further explored in large scale randomized studies.
Texto completo:
1
Base de dados:
WPRIM
Tipo de estudo:
Clinical_trials
/
Risk_factors_studies
Idioma:
Zh
Ano de publicação:
2019
Tipo de documento:
Article